Research Topics
Genomes and Genes | Oliver StoeltzingSummaryCountry: Germany Publications
| Collaborators
|
Detail Information
Publications
Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumorOliver Stoeltzing
Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042, Regensburg, Germany
Langenbecks Arch Surg 395:185-92. 2010..We proposed that (90)Y-DOTATOC could be used in a neoadjuvant intention for improving therapy of hepatic NET metastases...- Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytesSven A Lang
Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, Regensburg, Germany
Mol Cancer Ther 7:3509-18. 2008..Dual targeting of Raf and VEGFR2 appears to be a valid strategy for therapy of pancreatic cancer... 
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibitionChristina Hackl
Department of Surgery, University of Regensburg Medical Center, Franz Josef Straus Allee 11, 93042 Regensburg, Germany
BMC Cancer 10:668. 2010..Here we followed-up on our previous observation that inhibition of Hsp90 may increase ATF3 expression and sought to determine the role of ATF3 in colon cancer...- Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cellsSven A Lang
Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
Biochim Biophys Acta 1803:435-42. 2010..In conclusion, inhibition of mTORC2 may abrogate unfavorable signaling effects of mTOR inhibitors, hence providing a novel rationale for therapy... - Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancerJohannes Taeger
Department of Surgery, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
Mol Cancer Ther 10:2157-67. 2011..These data provide evidence that targeting FGFR/PDFGR/VEGFR with TKI258 may be effective in human pancreatic cancer and warrants further clinical evaluation... - Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesisChristian Moser
Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
Eur J Cancer 44:1577-86. 2008..In conclusion, the IGF-IR inhibitor NVP-AEW541 effectively disrupts IGF-I signalling and reduces pancreatic tumour growth. Hence, blocking IGF-IR could prove valuable for targeted therapy of pancreatic cancer... - Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental modelsChristina Hackl
Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
Surgery 147:704-12. 2010..In this study, we investigated the impact of HSP90 inhibition on liver regeneration in murine models... - ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivoChristian Moser
Department of Surgery, Regensburg Medical Center, Regensburg, Germany
BMC Cancer 8:206. 2008..We hypothesized that therapeutic inhibition of HIF-1alpha could be achieved by using a novel tubulin-binding agent (ENMD-1198). ENMD-1198 is an analog of 2-methoxyestradiol (2ME2) with antiproliferative and antiangiogenic activity... 
Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancerChristian Moser
Department of Surgery, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93053 Regensburg, Germany
Anticancer Res 32:2551-61. 2012..To evaluate the impact of heat-shock protein 90 (HSP90) blockade by the novel inhibitor NVP-AUY922, on tumor growth and angiogenesis in pancreatic cancer...- Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in miceSven A Lang
Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Regensburg, Germany
Hepatology 49:523-32. 2009..Hence, the concept of targeting tumor cells, ECs, and VSMCs by blocking Hsp90/mTOR could prove valuable for treatment of HCC... - Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivoChristian Moser
Department of Surgery, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
Mol Cancer Ther 6:2868-78. 2007..Hence, targeting Hsp90 could prove valuable for treatment of advanced colorectal cancer by effectively inhibiting colon cancer growth and hepatic metastasis and improving the efficacy of oxaliplatin... - Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitorsChristian Moser
Department of Surgery, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93053 Regensburg, Germany
Anticancer Res 32:427-37. 2012..To evaluate the effects of HSP90 blockade by EC154 on the oncogenic receptor tyrosine kinase macrophage-stimulating 1 receptor (MST1R) in gastric and pancreatic cancer... - Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alphaAkira Mori
Department of Surgery and Surgical Oncology, University of Regensburg Medical Center, Regensburg, Germany
Mol Cancer Res 7:1390-8. 2009..In conclusion, overexpression of KLF5 in human pancreatic cancer cells is not mediated by KRAS/Raf/MAPK/Erk signaling, but involves the IL-1beta/IL-1R system, p38, and the transcription factor HIF-1alpha... - Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental modelSven Arke Lang
Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
Langenbecks Arch Surg 393:333-41. 2008..We hypothesized that concomitant inhibition of Raf and vascular endothelial growth factor receptor 2 (VEGFR2) will affect tumor growth and angiogenesis of HCC... - Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancerChristian Moser
Department of Surgery, University of Regensburg Medical Center, 93042 Regensburg, Germany
Anticancer Res 29:2031-42. 2009..Against this background, the following review focuses on the current preclinical experience and value of targeting Hsp90 for the therapy of gastrointestinal carcinomas... - STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastasesChristian Moser
Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
Neoplasia 14:915-25. 2012..Taken together, our results suggest that STAT5b might be a potential novel target for human DPAC... - Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopSven A Lang
Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
Clin Cancer Res 13:6459-68. 2007....